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Abstract
Background: Tumor necrosis factor a (TNF-a) may have a pivotal role in the genesis of mechanical allodynia and
thermal hyperalgesia during inflammatory and neuropathic pain. Thalidomide has been shown to selectively inhibit
TNF-a production. Previous studies have suggested that thalidomide exerts anti-nociceptive effects in various pain
models, but its effects on bone cancer pain have not previously been studied. Therefore, in the present study, we
investigated the effect of thalidomide on bone cancer-induced hyperalgesia and up-regulated expression of spinal
TNF-a in a mouse model.
Results: Osteosarcoma NCTC 2472 cells were implanted into the intramedullary space of the right femurs of C3H/
HeJ mice to induce ongoing bone cancer related pain behaviors. At day 5, 7, 10 and 14 after operation, the
expression of TNF-a in the spinal cord was higher in tumor-bearing mice compared to the sham mice.
Intraperitoneal injection of thalidomide (50 mg/kg), started at day 1 after surgery and once daily thereafter until
day 7, attenuated bone cancer-evoked mechanical allodynia and thermal hyperalgesia as well as the up-regulation
of TNF-a in the spinal cord.
Conclusions: These results suggest that thalidomide can efficiently alleviate bone cancer pain and it may be a
useful alternative or adjunct therapy for bone cancer pain. Our data also suggest a role of spinal TNF-a in the
development of bone cancer pain.
Background
Primary bone cancers and cancers that metastasize to
bone often cause severe pain in humans [1,2]. This pain
is dull and constant, increases with time and is exacer-
bated by use of involved portions of the skeleton. Tumor
growth within the bone is accompanied by release of
inflammatory and tumorigenic components as well as
infiltration and compression of peripheral nerves, and
these factors contribute to the development of both
ongoing and movement-evoked pain [3,4]. Due to its
complex nature and multifactor origin, bone cancer pain
is difficult to manage and is relatively resistant to
morphine [5,6]. Hence, novel and more efficacious thera-
pies are urgently needed to deal with this condition.
Thalidomide is a relatively selective TNF-a synthesis
inhibitor which has been shown to inhibit TNF-a
production in vivo [7] and in vitro [8]. The ability of tha-
lidomide to inhibit TNF-a production, has been asso-
ciated with its clinical benefits in the treatment of many
immune inflammatory diseases. Previous studies have
demonstrated that thalidomide exerts anti-nociceptive
effects in rat models of neuropathic [9,10] and inflamma-
tory pain [11,12], and that the effects are due to the inhi-
bition of TNF-a production by resident inflammatory
cells. Moreover, thalidomide can also ameliorate pain-
related behaviors produced by taxol chemotherapy [13].
However, the effects of thalidomide on bone cancer pain
have not been previously investigated. The aim of the
present study was to evaluate the efficacy of thalidomide
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produced by injecting NCTC 2472 cells into the intrame-
dullary space of mouse femur [14].
It has been demonstrated that TNF-a is up-regulated
in the spinal cord during inflammatory [15] and neuro-
pathic pain [16]. Intrathecal administration of TNF-a
induces mechanical and thermal hyperalgesia and
enhances responses to C-fibre stimulation, wind-up phe-
nomenon and post-discharge of wide-dynamic range
neurons in the spinal cord dorsal horn of anaesthetized
rats [17,18]. Overexpression of TNF-a in spinal cord
astrocytes exacerbates mechanical allodynia induced by
spinal nerve transection [19]. Furthermore, intrathecal
administration of the soluble form of p75 Tumor necro-
sis factor receptor (TNFR) (etanercept) reduces pain-
related behaviors in animal models of inflammation [20]
and neuropathic pain [21]. These data support a role for
spinal cord TNF-a in the development of inflammatory
and neuropathic pain. However, whether spinal TNF-a
is involved in cancer-induced pain has not been investi-
gated. Therefore, in this study we also detected the
expression of spinal TNF-a in bone cancer pain and the
effects of thalidomide on bone cancer-induced TNF-a
expression, hypothesizing that thalidomide significantly
inhibits bone cancer-induced hyperalgesia and concomi-
tantly suppresses TNF-a expression in the spinal cord.
Results
Pain behaviors over time
The ipsilateral hind limb to the operation of both tumor
and sham mice displayed a significant decrease of paw
withdrawal mechanical threshold (PWMT) to von Frey
filaments stimulation at day 3 and the PWMT recovered
to the level of day 0 at day 5 (Fig. 1A). At day 7, Tumor-
bearing mice then showed a decrease of PWMT of the
ipsilateral hind limb which gradually decreased over time
until day 14, when the value was 0.43 ± 0.16 g.
The ipsilateral hind limb of both tumor and sham mice
displayed the decrease of paw withdrawal thermal latency
(PWTL) to radiant heat stimulation at day 3, and recov-
ered to the level before operation at day 5 (Fig. 1B). This
transient decrease of PWMT and PWTL at day 3 might
attribute to the arthrotomy. PWTL of the tumor-bearing
mice at day 10 showed a significant decrease and gradu-
ally decreased along with the development of bone can-
cer pain. At day 14, the value was 10.41 ± 1.35 s in
tumor-bearing mice. In addition, no significant differ-
ences in PWTL and PWMT were observed in sham mice
between days 5, 7, 10, 14 and day 0.
Effects of intraperitoneal administration of thalidomide
on pain behaviors induced by bone cancer pain
The paw withdrawal thresholds between tumor receiving
thalidomide group and tumor receiving vehicle group
were not significantly different until day 7 after opera-
tion (Fig. 2A). Compared with tumor receiving vehicle
group (1.07 ± 0.39) g, PWMT of tumor receiving thali-
domide group increased to 1.53 ± 0.39 g at day 7.
Although drug treatment was discontinued at day 7, this
anti-allodynia effect was maintained throughout day 14.
PWTL of tumor-bearing mice was ameliorated by
intraperitoneal administration of thalidomide (Fig. 2B).
At day 10 after operation, compared with tumor receiv-
ing vehicle group (12.64 ± 1.56) s, PWTL of tumor
receiving thalidomide group extended to 16.48 ± 1.13 s.
And the analgesic effect of thalidomide continued to
exist at day 14. Thalidomide itself had no effect on ther-
mal and mechanical nociceptive threshold in sham mice.
Measurement of TNF-a expression in the spinal cord of
tumor-bearing mice
The expression of TNF-a was significantly up-regulated
in cancer mice compared with that of sham control, as
revealed by Western blot. (Fig. 3A, B). Compared with
sham mice (0.27 ± 0.05) and preoperative levels (0.27 ±
0.08), spinal TNF-a levels were increased at day 5
(1.46 ± 0.15) after operation and this increase persisted at
day 7 (1.09 ± 0.15), day 10 (1.18 ± 0.09) and day 14 (1.14
± 0.19). No significant differences in TNF-a levels were
observed between sham mice and preoperative levels.
Effects of intraperitoneal administration of thalidomide
on spinal TNF-a expression
Intraperitoneal administration of thalidomide decreased
the expression of TNF-a in the spinal cord at day 7
(Fig. 4A, B) and 14 (Fig. 4C, D) after operation. At day 7,
spinal TNF-a levels of tumor receiving thalidomide
group (0.69 ± 0.06) was significantly decreased compared
with that of tumor receiving vehicle group (1.28 ± 0.15).
Although drug treatment was discontinued on day 7,
compared with tumor receiving vehicle group, tumor
receiving thalidomide group still showed a decrease in
the expression of TNF-a at day 14 after operation. There
were no differences in TNF-a expression between sham
receiving thalidomide mice and sham receiving vehicle
mice.
Discussion
Pain is a common and debilitating symptom of cancer.
Tumor growth is accompanied by infiltration and com-
pression of peripheral nerves as well as release of
inflammatory and tumorigenic components, and these
factors contribute to the generation of both ongoing and
movement-evoked pain. TNF-a is a potent pro-inflam-
matory cytokine which can be produced by tumor cells
and recruited inflammatory cells at the tumor site.
Recent evidence suggests that TNF-a may affect
bone cancer-related hyperalgesia. In the calcaneus
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Page 2 of 10Figure 1 Changes of pain behaviors of the right hind limb over time in tumor-bearing mice and sham mice.( A )P W M Tt ov o nF r e y
filaments of tumor-bearing mice decreased as time went on after day 7. (B) PWTL of tumor-bearing mice decresaed gradually after day 10. 0, 3,
5, 7,10 and 14 d indicate days after NCTC2472 cells innoculation to the femur. Data are expressed as means ± SD.
#P < 0.05 vs sham mice,
*P < 0.05 vs day 0.
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Page 3 of 10Figure 2 The effect of intraperitoneal administration of thalidomide on pain-related behaviors produced by bone cancer pain.P W M T
to von Frey filament stimulation (A) and PWTL to thermal stimulation stimulation (B) were ameliorated after treatment with thalidomide.
Thalidomide (50 mg/kg) was applied on 1 d after operation and then once daily thereafter until day 7. Thalidomide alone did not affect the
behavior response in sham mice (A, B). All data points represent mean ± SD (n = 6 per group). * P < 0.05 vs tumor + vehicle group.
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Page 4 of 10cancer pain model, Wacnik et al [22] found that
TNF-a was released at the tumor site and systemic
pre-implantation as well as local post-implantation
injection of the soluble receptor antagonist TNFR:Fc
could partially block ongoing tumor-associated
mechanical hyperalgesia. Constantin et al [23] reported
that TNF-a induced cancer-related heat hyperalgesia
was linked to upregulation of transient receptor poten-
tial vanilloid 1 (TRPV1), and systemic treatment with
etanercept could prevent tumor-induced nociceptor
sensitization. Moreover, in TNFR knock-out mice, a
significant reduction in tactile allodynia is observed
after tumor cell inoculation [24]. In addition, there is
in vitro evidence that TNF-a produced by cancer cells
may be responsible for stimulation of osteoclast activ-
ity and the resulting bone resorption [25]. These data
suggest that local production of TNF-a may contribute
to tumor-induced nociception and raise the possibility
that TNF-a antagonists or receptor blockers may be
useful in treating cancer pain. Accordingly, first case
reports show analgesic effects of TNF antagonists in
patients with treatment-refractory pain caused by bone
metastases [26]. Similarly, in our study, we found that
intraperitoneal injection of TNF-a synthesis inhibitor
thalidomide was effective in reducing tumor-induced
mechanical allodynia and thermal hyperalgesia. Our
results provide further support for the use of TNF-a
antagonism as a means of reducing cancer pain, parti-
cularly bone cancer pain.
Many previous studies have shown the antinociceptive
effect of thalidomide in several models of peripheral
inflammation [11,12,27] and nerve injury [9,10,16]. The
antinociceptive effect correlated with the inhibition of
TNF-a production. Interestingly, in these studies, only
Figure 3 Time course of spinal TNF-a changes after tumor cells innoculation to the bone. Tumor induced up-regulation of the TNF-a
expression within the spinal cord. (A) Bands of Western blot of the TNF-a expression (26 KDa). b-actin is a loading control. (B) Statistical analysis
of relative density of Western blot between tumor and sham mice. * P < 0.05 vs sham mice.
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Page 5 of 10pre-emptive treatment with thalidomide could attenuate
mechanical allodynia and thermal hyperalgesia. More-
over, other drugs, including pentoxifylline and etaner-
cept, which inhibit production of TNF-a or of its
receptors, show anti-inflammatory and analgesic proper-
ties only when given preemptively [28,29]. These data
provide evidence that TNF-a may only participate in
the initiation of local inflammation and neuropathic
pain [30]. Our previous studies have shown that the
establishment of the mouse femur cancer pain model
takes approximately two weeks [31,32]. Therefore, in the
present study, thalidomide was treated in the initial
seven days after operation, which is similar with the pre-
emptive treatment. We also found that thalidomide had
no significant effect on PWMT and PWTL of sham
mice, excluding non-specific effects of thalidomide on
pain perception.
In our study, we found thalidomide treatment attenu-
ated the behavioral effects of bone cancer pain but did
not completely reverse them. We may not have selected
the optimal dose of thalidomide or, more likely, apart
from TNF-a, there may be involvement of additional
factors in bone cancer pain. For instance, other cyto-
kines like interleukin-1 may also contribute to the devel-
opment of pain in this animal model [33].
Spinal glial activation has been observed in several
bone cancer pain models [14,34,35]. Activated glial cells
are associated with the increased release of proinflamma-
tory cytokines, which may be implicated in the hyperalge-
sia induced by injecting cancer cells into the bone [36].
The present study further demonstrated that spinal TNF-
a was significantly up-regulated in tumor-bearing mice
and intraperitoneal injection of thalidomide decreased
spinal TNF-a expression as well as bone cancer-induced
mechanical allodynia and thermal hyperalgesia. These
data are consistent with previous reports that spinal
TNF-a is up-regulated during inflammatory [15] and
neuropathic pain [16]. Intrathecal administration of eta-
nercept reduces pain-related behaviors in animal models
of inflammation [20] and neuropathic pain [21]. In the
Figure 4 Spinal TNF-a changes after intraperitoneal administration of thalidomide. Thalidomide decreased the expression of TNF-a in the spinal
cord at day 7 (A, B) and 14 (C, D) after operation. (A, C) Bands of Western blot of the TNF-a expression (26 KDa). b-actin is a loading control. (B, D)
Statistical analysis of relative density of Western blot between four groups. * P < 0.05 vs tumor + vehicle group,
#P < 0.05 vs sham + vehicle group.
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cancer-induced TNF-a up-regulation may be responsible
for the development of mechanical allodynia and thermal
hyperalgesia. However, as thalidomide is only a relatively
selective TNF-a synthesis inhibitor that can also inhibit
interleukins (IL) 1b, 6, 12, and granulocyte macrophage-
colony stimulating factor (GM-CSF) [37]. Moreover, the
drug was administered systematically in our study.
Hence, further studies with intrathecal TNF-a receptor
antagonists are necessary to demonstrate the potential
role of TNF-a in the development of bone cancer pain.
Consistent with our study, previous studies have sug-
gested that systematic treatment with thalidomide sup-
presses spinal TNF-a expression during neuropathic
pain [16] and spinal cord ischemia/reperfusion injury
[38]. We suppose that there are two possible mechan-
isms that may contribute to the decrease of spinal TNF-
a after treatment with thalidomide. First, as thalidomide
has good central nervous system penetration, it may act
directly on the glial cells in the spinal cord and decrease
the synthesis of TNF-a. Second, thalidomide inhibits
TNF-a release at the tumor site and reduces peripheral
nociceptive inputs to reach the spinal cord, which may
inhibit glial activation and subsequent spinal release of
proinflammatory cytokines.
Conclusions
In summary, the present study demonstrated that bone
cancer induced mechanical allodynia and thermal hyper-
algesia as well as the up-regulation of TNF-a in the
spinal cord. We found that TNF-a synthesis inhibitor
thalidomide decreased the bone cancer related pain
behaviors as well as the up-regulation of TNF-a in the
spinal cord. Our study suggests that thalidomide may be
an effective novel option for the treatment of bone can-
cer pain. We also provide evidence that spinal TNF-a
may participate in the development of bone cancer pain.
Methods
Animals
Adult (4-6 weeks old) male C3H/HeJ mice weighing 20-
25 g were used for this study. Animals were obtained
from the Model Animal Research Center of Nanjing
University, housed on a 12-hour light/dark schedule,
and allowed ad libitum access to food and water. All
experiments were approved by the Animal Care and
Use Committee at the college and were in accordance
w i t ht h eg u i d e l i n e sf o rt h eu s eo fl a b o r a t o r ya n i m a l s
[39]. All efforts were made to minimize animal suffering
and to reduce the number of animals used.
Cell culture and implantation
Osteosarcoma NCTC 2472 cells (American Type Cul-
ture Collection, ATCC, 2087787) were incubated and
subcultured in NCTC 135 medium (Sigma-Aldrich,
St. Louis, USA) with 10% horse serum (Gibco, Grand
I s l a n d ,U S A )a t3 7 ° Ci na na t m o s p h e r eo f5 %C O 2a n d
95% air (Thermo Forma, Ohio, USA), and passaged
twice a week according to ATCC recommendations.
The mouse model of bone cancer pain was performed as
previously described by Schwei [14]. Briefly, mice were
anesthetized with intraperitoneal injection of 50 mg/kg
pentobarbital sodium (1% in normal saline), and a superfi-
cial incision was made in the skin overlying the right
articulatio genu with eye scissors. Gonarthrotomy was per-
formed, exposing the femur condyles. A light depression
was made using a dental bur. A 30-gauge needle was used
to perforate the cortex, then a 25 μl microsyringe was
u s e dt oi n j e c tav o l u m eo f2 0μl a-minimum essential
medium (a-MEM) containing no or 10
5 NCTC 2472 cells
into the intramedullary space of the femur, corresponding
to sham or tumor-bearing mice. Afterwards, the injection
hole was sealed with dental amalgam, followed by copious
irrigation with normal saline. The wound was then closed.
Drug preparation
Thalidomide (Tocris Bioscience, Missouri, USA) was
dissolved in dimethylsulfoxide (DMSO) and then diluted
in saline to a final concentration of 10 mg/ml (the con-
centration of DMSO was 10%, v/v). 10% DMSO was
also used for vehicle treatment. In the thalidomide trea-
ted groups, thalidomide was injected (50 mg/kg) intra-
peritoneally (i.p.) at day 1 after operation and then daily
thereafter until the 7th day. The control group received
corresponding volume of vehicle injection.
Experimental protocol
78 mice were used in the study. The study included four
independent experiments and different animals were
used in each experiment.
Experiment 1: pain behaviors over time
We examined the time course of changes in behavior after
tumor inoculated to the bone. Withdrawal threshold and
latency to mechanical and thermal stimulation respectively
were examined during a 2-week period: day 0 before
operation and on days 3, 5, 7, 10 and 14 after operation in
both tumor-bearing mice (n = 6) and sham (n = 6) mice.
Experiment 2: Effects of intraperitoneal administration of
thalidomide on pain behaviors induced by bone cancer
pain
To examine the effects of thalidomide on bone cancer-
induced pain behaviors, thalidomide was intraperitone-
ally given at day 1 after operation and then once daily
f o r7d a y s .F o u rg r o u p so fm i c e( n=6 / g r o u p )w e r e
used, which included: (1) tumor + vehicle; (2) tumor
+ thalidomide (50 mg/kg); (3) sham + vehicle; (4)
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and mechanical allodynia were tested on day 0 (base-
line) and postoperative days 3, 5, 7, 10, and 14.
Experiment 3: Measurement of TNF-a expression in the
spinal cord of tumor-bearing mice
To determine whether bone cancer would change the
expression of TNF-a in the L3-L5 spinal cord, we used five
groups of mice (n = 3/group) to obtain tissue samples
(Western blot) on day 0 and postoperative day 5, 7, 10, or
14 from tumor-bearing mice. One group of sham-operated
mice (n = 3) was used as control, and their spinal cord
samples were removed on postoperative day 14.
Experiment 4: Effects of intraperitoneal administration of
thalidomide on the expression of TNF-a in the spinal
cord
To determine whether thalidomide would change the
expression of TNF-a in the L3-L5 spinal cord, eight
groups of mice (n = 3/group) were used, which
included: (1) tumor + vehicle (7 d, 14 d); (2) tumor +
thalidomide (7 d, 14 d); (3) sham + vehicle (7 d, 14 d);
(4) sham + thalidomide (7 d, 14 d). Tissue samples
(Western blot) were obtained at day 7 and 14 after
operation.
Mechanical allodynia
Mechanical allodynia was assessed by using von Frey
filaments (Stoelting, Wood Dale, IL) as described by Tal
and Bennett [40]. Animals were placed in individual
plastic boxes (10×10×15 cm) on a metal mesh floor and
allowed to acclimatize for 30 min. Mechanical threshold
was measured using a set of von Frey filaments (0.16 g,
0.4 g, 0.6 g, 1.0 g, 1.4 g, 2.0 g). The filaments were per-
pendicular to the plantar surface with sufficient force to
cause slight bending against the paw and were held for
6-8 s with a 10-min interval between each stimulation.
The positive response was defined as a withdrawal of
hind paw upon the stimulus. The paw withdrawal
mechanical threshold (PWMT) was determined by
sequentially increasing and decreasing the stimulus
strength. Each mouse was tested 5 times per stimulus
strength. The lowest von Frey filaments which had 3 or
more positive responses were regarded as PWMT.
Thermal hyperalgesia
Thermal hyperalgesia to radiant heat was determined
according to a method described by Hargreaves et al
[41]. In brief, mice were placed in clear plastic cages on
an elevated glass plate and allowed to acclimatize for 30
min before testing. A radiant thermal stimulator
(BME410A, Institute of Biological Medicine, Academy
of Medical Science, China) was focused onto the plantar
surface of the hindpaw through the glass plate. The
nociceptive end-points in the radiant heat test were the
characteristic lifting or licking of the hindpaw, and the
time to the end-point was considered the paw withdra-
w a lt h e r m a ll a t e n c y( P W T L ) .T h ec u t o f ft i m eo f2 0s
was used to avoid tissue damage. There were five trials
per mouse and 5 min intervals between trials. The mean
PWTL was obtained from the latter three stimuli.
Western Blotting
Mice were rapidly (< 1 min) killed through decapitation
after being anesthetized with pentobarbital, and the
L3-L5 lumbar spinal cord segments were removed
rapidly and stored in liquid nitrogen. Tissue samples
were homogenized in lysis buffer. The homogenate was
centrifuged at 13,000 rpm for 10 min at 4°C and super-
natant was removed. The protein concentration was
determined by the BCA Protein Assay Kit, following the
manufacturer’s instructions. Samples (50 μg) were sepa-
rated on SDS-PAGE (12%) and subsequently transferred
to polyvinylidene difluoride membranes (Millopore Cor-
poration, MA, USA). The filter membranes were
blocked with 5% nonfat milk for 1 h at room tempera-
ture and incubated with goat anti-TNF-a primary anti-
body (1:500, Santa Cruz Biotechnology, CA, USA). The
membrane was washed with TBST buffer and incubated
for 1 h with the secondary antibody conjugated with
horseradish peroxidase (1:5000; BioVision, CA, USA) for
1 h at room temperature. Next, the immune complexes
were detected using the ECL system (Santa Cruz
Biotechnology, CA, USA). b-actin was used as a loading
control for total protein. The images of Western blot
products were collected and analyzed by Quantity One
V4.31 (Bio-Rad, USA).
Statistical Analysis
All data are expressed as mean ± SD (standard devia-
tion). Repeated measures ANOVA was performed to
determine overall differences at each time point in
PWMT and PWTL. One-way ANOVA was used to
determine differences in the expression of TNF-a
among all experiment groups. In both cases, when
significant main effects were observed, LSD post hoc
tests were performed to determine the source(s) of dif-
ferences. A P value < 0.05 was considered statistically
significant.
List of abbreviations used
TNF-a: Tumor necrosis factor a; PWMT: paw withdra-
wal mechanical threshold; PWTL: paw withdrawal ther-
mal latency; TNFR: Tumor necrosis factor receptor;
TRPV1: transient receptor potential vanilloid 1; DMSO:
dimethylsulfoxide.
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